In the trenches on the medicine wards and smoking cessation clinics at Parkland Hospital and UT Southwestern Simmons Cancer Center, I see firsthand the increased prevalence of smoking in the Black population, their frequent use of menthol, and the ravaging toll it takes on their health.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
